Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
46 participants
INTERVENTIONAL
2015-08-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following are evaluated in this trial; Characteristics and safety/Tolerability Of CKD-391.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TR group
CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
CKD-391
Investigational product is prescribed to all of randomized subjects for two times.
Atrovastatin and Ezetimibe combination therapy
Investigational products are prescribed to all of radomized subjects for two times.
RT group
combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
CKD-391
Investigational product is prescribed to all of randomized subjects for two times.
Atrovastatin and Ezetimibe combination therapy
Investigational products are prescribed to all of radomized subjects for two times.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CKD-391
Investigational product is prescribed to all of randomized subjects for two times.
Atrovastatin and Ezetimibe combination therapy
Investigational products are prescribed to all of radomized subjects for two times.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed the informed consent form prior to the study participation
Exclusion Criteria
* Subject has signs of symptoms of acute disease within 28 days of starting administration of investigational drug
* Clinically significant allergic disease
* Impossible to taking the institutional standard meal
* Previously donate whole blood within 60 days or component blood within 20 days
* Previously participated in other trial within 90 days
* Continued to be taking caffeine (caffeine \> 5 cup/day), drinking(alcohol \> 30 g/day) or cannot stop drinking or severe heavy smoker(cigarette \> 10 cigarettes per day)during clinical trials
* An impossible one who participates in clinical trial by investigator's decision including laboratory test result
19 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chong Kun Dang Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Choon Ok Kim, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
152BE15026
Identifier Type: -
Identifier Source: org_study_id